These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 33318347)

  • 1. Neuromodulation Options and Patient Selection for Parkinson's Disease.
    Rajan R; Skorvanek M; Magocova V; Siddiqui J; AlSinaidi OA; Shinawi HM; AlSubaie F; AlOmar N; Deogaonkar M; Bajwa JA
    Neurol India; 2020; 68(Supplement):S170-S178. PubMed ID: 33318347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of subcutaneous infusion of apomorphine in Parkinson's disease.
    Wenzel K; Homann CN; Fabbrini G; Colosimo C
    Expert Rev Neurother; 2014 Jul; 14(7):833-43. PubMed ID: 24917215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EuroInf 2: Subthalamic stimulation, apomorphine, and levodopa infusion in Parkinson's disease.
    Dafsari HS; Martinez-Martin P; Rizos A; Trost M; Dos Santos Ghilardi MG; Reddy P; Sauerbier A; Petry-Schmelzer JN; Kramberger M; Borgemeester RWK; Barbe MT; Ashkan K; Silverdale M; Evans J; Odin P; Fonoff ET; Fink GR; Henriksen T; Ebersbach G; Pirtošek Z; Visser-Vandewalle V; Antonini A; Timmermann L; Ray Chaudhuri K;
    Mov Disord; 2019 Mar; 34(3):353-365. PubMed ID: 30719763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamics of device-based treatments for Parkinson's disease in Germany from 2010 to 2017: application of continuous subcutaneous apomorphine, levodopa-carbidopa intestinal gel, and deep brain stimulation.
    Richter D; Bartig D; Jost W; Jörges C; Stumpe B; Gold R; Krogias C; Tönges L
    J Neural Transm (Vienna); 2019 Jul; 126(7):879-888. PubMed ID: 31222604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selecting deep brain stimulation or infusion therapies in advanced Parkinson's disease: an evidence-based review.
    Volkmann J; Albanese A; Antonini A; Chaudhuri KR; Clarke CE; de Bie RM; Deuschl G; Eggert K; Houeto JL; Kulisevsky J; Nyholm D; Odin P; Østergaard K; Poewe W; Pollak P; Rabey JM; Rascol O; Ruzicka E; Samuel M; Speelman H; Sydow O; Valldeoriola F; van der Linden C; Oertel W
    J Neurol; 2013 Nov; 260(11):2701-14. PubMed ID: 23287972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. European Academy of Neurology/Movement Disorder Society-European Section Guideline on the Treatment of Parkinson's Disease: I. Invasive Therapies.
    Deuschl G; Antonini A; Costa J; Śmiłowska K; Berg D; Corvol JC; Fabbrini G; Ferreira J; Foltynie T; Mir P; Schrag A; Seppi K; Taba P; Ruzicka E; Selikhova M; Henschke N; Villanueva G; Moro E
    Mov Disord; 2022 Jul; 37(7):1360-1374. PubMed ID: 35791767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. European Academy of Neurology/Movement Disorder Society - European Section guideline on the treatment of Parkinson's disease: I. Invasive therapies.
    Deuschl G; Antonini A; Costa J; Śmiłowska K; Berg D; Corvol JC; Fabbrini G; Ferreira J; Foltynie T; Mir P; Schrag A; Seppi K; Taba P; Ruzicka E; Selikhova M; Henschke N; Villanueva G; Moro E
    Eur J Neurol; 2022 Sep; 29(9):2580-2595. PubMed ID: 35791766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost analysis of the treatments for patients with advanced Parkinson's disease: SCOPE study.
    Valldeoriola F; Puig-Junoy J; Puig-Peiró R;
    J Med Econ; 2013; 16(2):191-201. PubMed ID: 23035627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic review of apomorphine infusion, levodopa infusion and deep brain stimulation in advanced Parkinson's disease.
    Clarke CE; Worth P; Grosset D; Stewart D
    Parkinsonism Relat Disord; 2009 Dec; 15(10):728-41. PubMed ID: 19805000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advanced stages of PD: interventional therapies and related patient-centered care.
    Krüger R; Hilker R; Winkler C; Lorrain M; Hahne M; Redecker C; Lingor P; Jost WH
    J Neural Transm (Vienna); 2016 Jan; 123(1):31-43. PubMed ID: 26138439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson's disease.
    Martinez-Martin P; Reddy P; Katzenschlager R; Antonini A; Todorova A; Odin P; Henriksen T; Martin A; Calandrella D; Rizos A; Bryndum N; Glad A; Dafsari HS; Timmermann L; Ebersbach G; Kramberger MG; Samuel M; Wenzel K; Tomantschger V; Storch A; Reichmann H; Pirtosek Z; Trost M; Svenningsson P; Palhagen S; Volkmann J; Chaudhuri KR
    Mov Disord; 2015 Apr; 30(4):510-6. PubMed ID: 25382161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protocol of a randomized open label multicentre trial comparing continuous intrajejunal levodopa infusion with deep brain stimulation in Parkinson's disease - the INfusion VErsus STimulation (INVEST) study.
    van Poppelen D; Sisodia V; de Haan RJ; Dijkgraaf MGW; Schuurman PR; Geurtsen GJ; Berk AEM; de Bie RMA; Dijk JM
    BMC Neurol; 2020 Jan; 20(1):40. PubMed ID: 32005175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Motor features and response to oral levodopa in patients with Parkinson's disease under continuous dopaminergic infusion or deep brain stimulation.
    Elia AE; Dollenz C; Soliveri P; Albanese A
    Eur J Neurol; 2012 Jan; 19(1):76-83. PubMed ID: 21645174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-Effectiveness of Device-Aided Therapies in Parkinson's Disease: A Structured Review.
    Smilowska K; van Wamelen DJ; Pietrzykowski T; Calvano A; Rodriguez-Blazquez C; Martinez-Martin P; Odin P; Chaudhuri KR
    J Parkinsons Dis; 2021; 11(2):475-489. PubMed ID: 33386813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continuous subcutaneous apomorphine infusion in Parkinson's disease: causes of discontinuation and subsequent treatment strategies.
    Olivola E; Fasano A; Varanese S; Lena F; Santilli M; Femiano C; Centonze D; Modugno N
    Neurol Sci; 2019 Sep; 40(9):1917-1923. PubMed ID: 31111272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Device-aided therapies in advanced Parkinson's disease].
    Timofeeva AA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(12):54-60. PubMed ID: 28139627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Continuous Subcutaneous Infusion Delivery of Apomorphine in Parkinson's Disease: A Systematic Review.
    Kukkle PL; Garg D; Merello M
    Mov Disord Clin Pract; 2023 Sep; 10(9):1253-1267. PubMed ID: 37772305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Where are we with surgical therapies for Parkinson's disease?
    Strauss I; Kalia SK; Lozano AM
    Parkinsonism Relat Disord; 2014 Jan; 20 Suppl 1():S187-91. PubMed ID: 24262178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advanced Parkinson's disease: clinical characteristics and treatment. Part II.
    Kulisevsky J; Luquin MR; Arbelo JM; Burguera JA; Carrillo F; Castro A; Chacón J; García-Ruiz PJ; Lezcano E; Mir P; Martinez-Castrillo JC; Martínez-Torres I; Puente V; Sesar A; Valldeoriola-Serra F; Yañez R
    Neurologia; 2013; 28(9):558-83. PubMed ID: 23880230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. When the going gets tough: how to select patients with Parkinson's disease for advanced therapies.
    Worth PF
    Pract Neurol; 2013 Jun; 13(3):140-52. PubMed ID: 23487815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.